Headlines about RXi Pharmaceuticals Corporation (NASDAQ:RXII) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. RXi Pharmaceuticals Corporation earned a media sentiment score of 0.03 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.8978776532302 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news stories that may have impacted Accern’s rankings:
- RXi Pharmaceuticals Corporation (RXII) vs. Immunomedics (IMMU) Head to Head Contrast (americanbankingnews.com)
- RXi Pharmaceuticals Corporation (RXII) – Lookout Unusual Volume stock – Wall Street Morning (wallstreetmorning.com)
- RXi Pharmaceuticals to Present at the 2017 Annual BIO Investor Forum – PR Newswire (press release) (prnewswire.com)
Shares of RXi Pharmaceuticals Corporation (RXII) traded up 6.00% on Tuesday, reaching $0.53. 522,159 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $0.52 and a 200-day moving average price of $0.60. RXi Pharmaceuticals Corporation has a 12-month low of $0.32 and a 12-month high of $2.93. The company’s market cap is $12.32 million.
RXi Pharmaceuticals Corporation (NASDAQ:RXII) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.11). During the same quarter in the previous year, the business earned ($0.34) EPS. Equities research analysts anticipate that RXi Pharmaceuticals Corporation will post ($1.77) EPS for the current fiscal year.
In other news, insider Alexey Eliseev sold 176,800 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $0.54, for a total transaction of $95,472.00. Following the sale, the insider now owns 1,100,931 shares of the company’s stock, valued at approximately $594,502.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 5.71% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece was first published by BBNS and is the property of of BBNS. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://baseballnewssource.com/markets/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-rxi-pharmaceuticals-corporation-rxii-share-price/1699696.html.
RXi Pharmaceuticals Corporation Company Profile
RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.
Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with our FREE daily email newsletter.